EDMONTON, ALBERTA--(Marketwire - July 10, 2008) - ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumours, today released amended and restated audited financial statements for the year ended December 31, 2007. In addition the Company has updated and amended its Annual Report on Form 20-F that includes the audited consolidated financial statements for the year ended December 31, 2007.
